Battle Over Cost of Drugs Ratchets Up


[author: Nick Manetto]

The battle over the rising costs of drugs, fueled by Gilead’s Hepatitis C drug Sovaldi that costs $84,000 for a 12 week treatment regimen, intensified this week. Critics of the cost have taken to referring to the drug as the “1,000-a-day” pill. Earlier this week, the National Coalition on Health Care launched its Campaign for Sustainable Rx Pricing focused on the “unsustainable and abusive” prices of some drugs and that calls for finding “market-based solutions” to the issue. The Coalition, led by John Rother, the longtime AARP lobbyist, consists of many patient advocacy organizations as well as payers, unions and employers. Corporate members include Duke Energy, CVS Caremark, Premier and Verizon. Earlier in the year, state Medicaid programs and Medicaid Managed Care Organizations (MCOs) were among the first payers to express concerns given that many patients with the disease are Medicaid beneficiaries, and several state have acted to limit coverage of the drug.

On the other side of the issue is the biopharmaceutical industry, which argues that such novel treatments help improve lives and, in some cases, lead to lower healthcare costs over time. In the case of Sovaldi, advocates note that the treatment is far less costly – and less complicated – than a liver transplant. While expensive drugs are not new, Sovaldi is unique because of the more than 3 million U.S. patients who could benefit from the therapy and because of its superiority over existing treatment options: Following the treatment regimen, 90 percent of patients are cured of the disease.

Caught in the middle of the debate are patients and providers who typically want new and better treatments but also want them to be accessible and affordable. For proponents of Sovaldi and other novel therapies, demonstrating the economic benefits of the treatment over the long run may be helpful in pleading their case for coverage. At the same time, with the insurance market more fluid, payers have noted that there is no guarantee they will be the ones to realize the benefits should they cover a regimen only to have the now-cured patient move to another plan.

As one would expect, the issue has led some to compare the prices of the drug in the United States to costs in other nations that enact price controls. And earlier this year, leading Democratic members of the Energy & Commerce committee sent a letter to Gilead’s CEO asking questions about the pricing of the drug.


Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Faegre Baker Daniels | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.